iRhythm Holdings, Inc. (IRTC)
| Market Cap | 3.38B -40.7% |
| Revenue (ttm) | 825.34M +25.6% |
| Net Income | -13.95M |
| EPS | -0.43 |
| Shares Out | 32.96M |
| PE Ratio | n/a |
| Forward PE | 146.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 668,322 |
| Open | 104.41 |
| Previous Close | 104.99 |
| Day's Range | 100.70 - 104.41 |
| 52-Week Range | 100.70 - 212.00 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 173.93 (+69.52%) |
| Earnings Date | Nov 5, 2026 |
About IRTC
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for IRTC stock is "Strong Buy." The 12-month stock price target is $173.93, which is an increase of 69.52% from the latest price.
News
iRhythm price target lowered to $150 from $168 at Wells Fargo
Wells Fargo lowered the firm’s price target on iRhythm (IRTC) to $150 from $168 and keeps an Overweight rating on the shares. The firm is updating its IRTC model following…
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a...
iRhythm provides update on cybersecurity incident previously disclosed in June
“iRhythm (IRTC) provided an update regarding the cybersecurity incident previously disclosed in June, 2026. Following completion of the forensic investigation and subsequent review to determine the na...
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals
iRhythm Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
The acquisition of VitalConnect expands the product portfolio to fully address the MCT market, leveraging differentiated technology and a larger sales force for nationwide growth. Ambitions include reaching 30%-40% MCT market share, maintaining strong EBITDA margins, and driving innovation through EHR integration and multi-vitals capabilities.
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent di...
iRhythm price target lowered to $168 from $180 at Wells Fargo
Wells Fargo lowered the firm’s price target on iRhythm (IRTC) to $168 from $180 and keeps an Overweight rating on the shares. The firm cites the Q2 sales and margins…
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
iRhythm price target raised to $168 from $160 at Truist
Truist raised the firm’s price target on iRhythm (IRTC) to $168 from $160 and keeps a Buy rating on the shares. The firm cites the company’s Q2 beat and guidance…
iRhythm price target lowered to $192 from $255 at Needham
Needham lowered the firm’s price target on iRhythm (IRTC) to $192 from $255 and keeps a Buy rating on the shares. The fir reduced the stock’s target multiple following the…
iRhythm price target raised to $165 from $150 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on iRhythm (IRTC) to $165 from $150 and keeps an Outperform rating on the shares.
iRhythm price target raised to $165 from $160 at Baird
Baird raised the firm’s price target on iRhythm (IRTC) to $165 from $160 and keeps an Outperform rating on the shares. The firm updated its model following Q2 beat and…
iRhythm price target raised to $196 from $157 at Canaccord
Canaccord raised the firm’s price target on iRhythm (IRTC) to $196 from $157 and keeps a Buy rating on the shares. The firm said they had a strong Q2 beat-and-raise…
iRhythm to acquire VitalConnect for total consideration of $287.5M
iRhythm (IRTC) Holdings announced that it and its wholly owned subsidiary, iRhythm Technologies, Inc., have entered into a definitive agreement to acquire Vital Connect, Inc., a privately held leader ...
iRhythm Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 20%+ revenue growth, record profitability, and margin expansion, driven by strong demand and operational discipline. The VitalConnect acquisition will expand cardiac monitoring capabilities and address new market segments, with integration expected to accelerate growth from 2027.
iRhythm Holdings Earnings release: Q2 2026
iRhythm Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
iRhythm Holdings Slides: Q2 2026
iRhythm Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
iRhythm Holdings Quarterly report: Q2 2026
iRhythm Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
iRhythm sees FY26 revenue $880M-$890M, consensus $881.17M
For the full year 2026, iRhythm (IRTC) expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting continued volume-led growth, gross margin ex...
iRhythm Holdings Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent di...
iRhythm initiated with an Overweight at Stephens
Stephens initiated coverage of iRhythm (IRTC) with an Overweight rating and $160 price target iRhythm specializes in remote cardiac monitoring and arrhythmia detection and its Zio platform has been ra...
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026
SAN FRANCISCO, July 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent di...
iRhythm price target lowered to $160 from $174 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $160 from $174 and keeps a Buy rating on the shares as part of a broader research…
iRhythm removed from Conviction List at William Blair
William Blair removed iRhythm (IRTC) from the firm’s Conviction List citing the expiration of the six month time horizon. There is no change in William Blair’s investment thesis, and its…
iRhythm price target lowered to $150 from $160 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on iRhythm (IRTC) to $150 from $160 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…